Carta Healthcare, whose software program platform applies AI to structured and unstructured information to lower the time and prices for information abstraction, has acquired Realyze Intelligence, which applies related expertise to oncology.
Based in 2019, San Francisco-based Carta Healthcare stated it applies each synthetic intelligence and professional scientific information abstractors to serve a variety of well being programs nationwide, from standalone group hospitals to giant educational medical facilities. It lists Mass Basic Brigham, CommonSpirit and Grady as amongst its well being system clients.
Realyze Intelligence was fashioned in 2020 as a portfolio firm of UPMC Enterprises, the innovation, commercialization and enterprise capital arm of UPMC. Its software program analyzes structured and unstructured information in digital well being data to determine very best sufferers for scientific trials and different analysis research. The corporate says its clinician-trained AI can assemble acceptable cohorts in seconds as an alternative of the standard hours or days the method consumes when carried out manually. Realyze Intelligence is utilized by most cancers facilities and is a part of the Memorial Sloan Kettering Most cancers Middle Innovation Hub. The CancerX Accelerator Program additionally chosen Realyze Intelligence as a part of its inaugural program earlier this yr.
Phrases of the acquisition weren’t disclosed.
A Realyze Intelligence evaluation discovered that by utilizing the software program, UPMC Hillman Most cancers Middle noticed seven occasions extra sufferers matched to trials and twice as many enrolled, in comparison with the identical timeframe with out utilizing the software program.
“We imagine information is the only most essential ingredient to enhance healthcare,” stated Brent Dover, CEO of Carta Healthcare, in a press release. “From scientific trials to scientific registries, clinicians face insurmountable quantities of knowledge ripe with beneficial data to enhance care practices and affected person outcomes. We’re impressed by Realyze Intelligence’s shared capacity to make use of clinician-trained AI and a human-in-the-loop method to maximise insights from scientific information, for scientific trials and most cancers registries.”
“Well being programs and pharmaceutical firms make investments billions yearly to determine and enroll sufferers for scientific trials—a course of that’s not solely pricey however labor-intensive and time-consuming,” stated Aaron Brauser, founder and CEO of Realyze Intelligence, in a press release. “Excessive-quality, well timed information is important for precisely figuring out eligible sufferers, but a lot of it stays trapped in EHRs and different programs. We’re excited to revolutionize scientific trial matching and reuse the info to reinforce analysis, optimize care pathways and enhance affected person outcomes with Carta Healthcare.”
